You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease

Park, K. T. MD, MS*; Crandall, Wallace V. MD; Fridge, Jacqueline MBChB; Leibowitz, Ian H. MD§; Tsou, Marc MD; Dykes, Dana M. H. MD, MS; Hoffenberg, Edward J. MD**; Kappelman, Michael D. MD, MPH††; Colletti, Richard B. MD‡‡

Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000441349.40193.aa
Clinical Review Articles
Abstract

Abstract: A health care system is needed where care is based on the best available evidence and is delivered reliably, efficiently, and less expensively (best care at lower cost). In gastroenterology, anti–tumor necrosis factor agents represent the most effective medical therapeutic option for patients with moderate-to-severe inflammatory bowel disease (IBD), but are very expensive and account for nearly a quarter of the cost of IBD care, representing a major area of present and future impact in direct health care costs. The ImproveCareNow Network, consisting of over 55 pediatric IBD centers, seeks ways to improve the value of care in IBD, curtailing unnecessary costs and promoting better health outcomes through systematic and incremental quality improvement initiatives. This report summarizes the key evidence to facilitate the cost-effective use of anti–tumor necrosis factor agents for patients with IBD. Our review outlines the scientific rationale for initiating cost-reducing measures in anti–tumor necrosis factor use and focuses on 3 implementable strategies and 4 exploratory considerations through practical clinical guidelines, as supported by existing evidence. Implementable strategies can be readily integrated into today's daily practice, whereas exploratory considerations can guide research to support future implementation.

In Brief

Article first Published online 21 January 2014

Author Information

*Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Center for Health Policy/Primary Care Outcomes Research, Stanford University School of Medicine, Palo Alto, California;

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio;

Northwest Pediatric Gastroenterology LLC, Randall Children's Hospital, Portland, Oregon;

§Children's Digestive Disease Program, Inova Fairfax Hospital for Children, Fairfax, Virginia;

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Eastern Virginia Medical School, Norfolk, Virginia;

Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio;

**Section of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Colorado Denver School of Medicine, Denver, Colorado;

††Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina; and

‡‡Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Vermont College of Medicine, Burlington, Vermont.

Reprints: K. T. Park, MD, MS, Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, 750 Welch Road, Suite 116, Palo Alto, CA 94304 (e-mail: ktpark@stanford.edu).

K. T. Park is supported by the National Institute for Health (DK094868A). W. V. Crandall: Abbott (Speaking/Consulting), Boehringer Ingelheim Pharma GmbH & Co., KG (Consulting), and AbbVie (Research Support); M. D. Kappelman: Janssen Biotech (Research Support) and Johnson & Johnson (Stock Ownership); and R. B. Colletti: Janssen Biotech (Consulting/Research Support) and Accordant Health Services (Consulting). The remaining authors have no conflicts of interest to disclose.

Received November 21, 2013

Accepted December 10, 2013

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.